Last updated on November 2019

A Study of Obinutuzumab Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)


Find a site near you

Start Over

Insititut Catala D'Oncologia

Hospitalet de Llobregat, Spain
1.23miles
  Connect »

Hospital Cl nic. Barcelona

Barcelona, Spain
2.43miles
  Connect »